Related Experiment Video
Updated: Dec 15, 2025
04:30
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
Published on: March 8, 2024
1.3K
The future of neuromuscular blocking agents.
Christiane G Stäuble1, Manfred Blobner
1Klinik für Anaesthesiologie und Intensivmedizin, Technische Universität München, Klinikum Rechts der Isar, Ismaninger Straße, München, Germany.
Current Opinion in Anaesthesiology
|July 7, 2020
Summary
New neuromuscular blocking agents offer rapid reversal with L-cysteine, but are not yet clinically available. Current practice relies on established agents like rocuronium-sugammadex for anesthesia.
Area of Science:
- Anesthesiology
- Pharmacology
- Drug Development
Background:
- Anesthesiologists seek ideal neuromuscular blocking agents (NMBAs) with rapid onset/offset and minimal side effects.
- Current NMBAs like succinylcholine have limitations.
- Established reversal agents like sugammadex are widely used.
Purpose of the Study:
- To review recent developments in neuromuscular blocking agents.
- To present established and novel reversal agents in anesthesia.
Main Methods:
- Literature review of recent advancements in NMBA and reversal agent research.
- Analysis of preclinical and clinical data on new compounds.
Main Results:
- New chlorofumarate NMBAs (e.g., gantacurium) show promise with rapid reversal by L-cysteine.
- Novel reversal agents like adamgammadex sodium and calabadions are under preclinical investigation.
- These new agents are not yet available for clinical use.
Conclusions:
- Recent neuromuscular research offers promising agents but requires further clinical validation.
- Established combinations like rocuronium-sugammadex remain crucial for current anesthesia practice.
- Future clinical studies will define the role of novel NMBAs and reversal agents.
More Related Videos
Related Concept Videos
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
779
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
779
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
2.6K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.6K
01:11Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
691
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
691
01:28Depolarizing Blockers: Mechanism of Action
2.4K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
2.4K
01:29Neuromuscular Junction And Blockade
4.4K
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
4.4K
01:28Classification of Skeletal Muscle Relaxants
2.9K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.9K